DOP2017000279A - Inhibidores de tirosina-cinasas - Google Patents
Inhibidores de tirosina-cinasasInfo
- Publication number
- DOP2017000279A DOP2017000279A DO2017000279A DO2017000279A DOP2017000279A DO P2017000279 A DOP2017000279 A DO P2017000279A DO 2017000279 A DO2017000279 A DO 2017000279A DO 2017000279 A DO2017000279 A DO 2017000279A DO P2017000279 A DOP2017000279 A DO P2017000279A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- kinase inhibitors
- thyrosine
- compounds
- tyrosine kinase
- btk
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación proporciona compuestos que son inhibidores de tirosina-cinasas, en particular inhibidores de la tirosina-cinasa de Bruton (BTK), y, por lo tanto, son útiles para el tratamiento de enfermedades que se pueden tratar mediante la inhibición de BTK tales como el cáncer, enfermedades autoinmunitarias, inflamatorias y tromboembólicas. También se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562170547P | 2015-06-03 | 2015-06-03 | |
US201562271689P | 2015-12-28 | 2015-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2017000279A true DOP2017000279A (es) | 2018-04-15 |
Family
ID=56118090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2017000279A DOP2017000279A (es) | 2015-06-03 | 2017-12-01 | Inhibidores de tirosina-cinasas |
Country Status (32)
Country | Link |
---|---|
US (4) | US20180162861A1 (es) |
EP (3) | EP3303334B1 (es) |
JP (2) | JP6646072B2 (es) |
KR (1) | KR102552653B1 (es) |
CN (2) | CN106459049B (es) |
AU (2) | AU2016270973B2 (es) |
CA (1) | CA2987335A1 (es) |
CL (2) | CL2017003073A1 (es) |
CO (1) | CO2017012947A2 (es) |
CR (1) | CR20170593A (es) |
DK (1) | DK3303334T3 (es) |
DO (1) | DOP2017000279A (es) |
EA (1) | EA039006B1 (es) |
ES (1) | ES2878030T3 (es) |
HK (1) | HK1252378A1 (es) |
HR (1) | HRP20211249T1 (es) |
HU (1) | HUE055419T2 (es) |
IL (2) | IL255946A (es) |
LT (1) | LT3303334T (es) |
MX (2) | MX2017015470A (es) |
MY (1) | MY190548A (es) |
PE (1) | PE20180521A1 (es) |
PH (1) | PH12017502203A1 (es) |
PL (1) | PL3303334T3 (es) |
PT (1) | PT3303334T (es) |
RS (1) | RS62290B1 (es) |
SG (1) | SG10201912443XA (es) |
SI (1) | SI3303334T1 (es) |
TN (1) | TN2017000501A1 (es) |
TW (2) | TWI732765B (es) |
UA (1) | UA124090C2 (es) |
WO (1) | WO2016196840A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150044271A1 (en) | 2012-02-27 | 2015-02-12 | O-Ray Pharma, Inc. | Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders |
CN104822681B (zh) | 2012-09-10 | 2018-01-30 | 普林斯匹亚生物制药公司 | 作为激酶抑制剂的吡唑并嘧啶化合物 |
JP6581506B2 (ja) | 2013-11-29 | 2019-09-25 | 株式会社ダイゾー | 内容物収容容器、それを用いた内容物収容製品、吐出製品および吐出装置 |
JP6504548B2 (ja) | 2014-02-21 | 2019-04-24 | プリンシピア バイオファーマ インコーポレイテッド | Btk阻害剤の塩および固体形態 |
ES2843323T3 (es) | 2014-12-18 | 2021-07-16 | Principia Biopharma Inc | Tratamiento de pénfigo |
WO2016196840A1 (en) * | 2015-06-03 | 2016-12-08 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
EP3414234B1 (en) * | 2015-10-14 | 2022-06-29 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
CN109790164B (zh) * | 2016-07-25 | 2022-01-25 | 内尔维亚诺医疗科学公司 | 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物 |
EP3585789A1 (en) * | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
US20210113568A1 (en) * | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
KR20210038877A (ko) | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
CA3224945A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
CN112689637B (zh) * | 2018-09-13 | 2023-11-10 | 橘生药品工业株式会社 | 咪唑并吡啶酮化合物 |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN113045484B (zh) * | 2019-12-27 | 2024-01-26 | 南京药石科技股份有限公司 | 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法 |
CN113149891B (zh) * | 2020-01-07 | 2024-02-02 | 南京药石科技股份有限公司 | 一种2-氨基-2-(1-甲基-4-哌啶基)乙醇的制备方法 |
KR20220130179A (ko) | 2020-01-20 | 2022-09-26 | 젠자임 코포레이션 | 재발성 다발성 경화증(rms)에 대한 치료용 티로신 키나제 저해제 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
MX2022012248A (es) * | 2020-03-30 | 2022-10-27 | Igia Pharmaceuticals Inc | Formulacion pediatrica de inhibidores de tirosina quinasa. |
JP2023537357A (ja) | 2020-08-14 | 2023-08-31 | ノバルティス アーゲー | ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用 |
JP2023550591A (ja) | 2020-11-02 | 2023-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | EGFR阻害薬としての置換1H-ピラゾロ[4,3-c]及び誘導体 |
CA3201936A1 (en) | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
JP2024501247A (ja) * | 2020-12-23 | 2024-01-11 | ジェンザイム・コーポレーション | 4-アミノ-3-(4-フェノキシフェニル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]ピリジン-2-オン誘導体およびその塩 |
EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
WO2022218430A1 (zh) * | 2021-04-16 | 2022-10-20 | 南京明德新药研发有限公司 | 咪唑并吡啶类化合物及其应用 |
EP4328226A1 (en) * | 2021-04-23 | 2024-02-28 | Hangzhou Solipharma Co., Ltd. | Tolebrutinib crystal form, amorphous form, preparation method therefor and use thereof |
EP4342468A1 (en) * | 2021-05-21 | 2024-03-27 | Hangzhou Solipharma Co., Ltd. | Tolebrutinib salt and crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof |
WO2022257845A1 (zh) | 2021-06-11 | 2022-12-15 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
US11793820B2 (en) * | 2021-09-24 | 2023-10-24 | Chadwick Donaldson | Dry powder foamable formulations for delivery of medicaments through the mucosa |
TW202334146A (zh) | 2021-12-21 | 2023-09-01 | 美商健臻公司 | (r)-1-(1-丙烯醯基哌啶-3-基)-4-胺基-3-(4-苯氧基苯基)-1h-咪唑並[4,5-c]吡啶-2(3h)-酮及其衍生物的晶型 |
WO2023172663A1 (en) * | 2022-03-09 | 2023-09-14 | Teva Pharmaceuticals International Gmbh | Solid state forms of tolebrutinib and of tolebrutinib salts |
US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
WO2023244587A1 (en) * | 2022-06-14 | 2023-12-21 | Genzyme Corporation | Methods of making tolebrutinib |
WO2023249980A1 (en) * | 2022-06-22 | 2023-12-28 | Genzyme Corporation | Methods of making modified btk inhibitors |
WO2024006406A1 (en) | 2022-06-30 | 2024-01-04 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis |
TW202406550A (zh) | 2022-08-03 | 2024-02-16 | 瑞士商諾華公司 | Nlrp3炎性小體抑制劑 |
US20240173313A1 (en) | 2022-10-11 | 2024-05-30 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
WO2024099242A1 (zh) * | 2022-11-07 | 2024-05-16 | 天津征程医药科技有限公司 | 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US7244744B2 (en) | 2001-11-01 | 2007-07-17 | Icagen, Inc. | Piperidines |
US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
CA2580343A1 (en) * | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics, Inc. | Imidazoquinoline compounds |
AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
EP2029597A4 (en) | 2006-05-31 | 2011-11-23 | Univ California | purine analogs |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
EP2530083B1 (en) | 2006-09-22 | 2016-04-27 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
LT2578585T (lt) * | 2010-05-31 | 2016-10-10 | Ono Pharmaceutical Co., Ltd. | Purinono darinys kaip btk kinazės inhibitorius |
WO2012158785A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
PL2710005T3 (pl) * | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
MX355728B (es) * | 2011-05-17 | 2018-04-27 | Univ California | Inhibidores de cinasas. |
ES2601219T3 (es) * | 2011-11-29 | 2017-02-14 | Ono Pharmaceutical Co., Ltd. | Clorhidrato de derivado de purinona |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
RU2679130C2 (ru) | 2012-07-11 | 2019-02-06 | Блюпринт Медсинс Корпорейшн | Ингибиторы рецептора фактора роста фибробластов |
CN104822681B (zh) * | 2012-09-10 | 2018-01-30 | 普林斯匹亚生物制药公司 | 作为激酶抑制剂的吡唑并嘧啶化合物 |
US20140142099A1 (en) * | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2016196840A1 (en) * | 2015-06-03 | 2016-12-08 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
EP3414234B1 (en) | 2015-10-14 | 2022-06-29 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
-
2016
- 2016-06-02 WO PCT/US2016/035588 patent/WO2016196840A1/en active Application Filing
- 2016-06-02 UA UAA201712794A patent/UA124090C2/uk unknown
- 2016-06-02 PL PL16728566T patent/PL3303334T3/pl unknown
- 2016-06-02 MX MX2017015470A patent/MX2017015470A/es unknown
- 2016-06-02 KR KR1020177037609A patent/KR102552653B1/ko active IP Right Grant
- 2016-06-02 SI SI201631244T patent/SI3303334T1/sl unknown
- 2016-06-02 ES ES16728566T patent/ES2878030T3/es active Active
- 2016-06-02 EP EP16728566.7A patent/EP3303334B1/en active Active
- 2016-06-02 TW TW105117466A patent/TWI732765B/zh active
- 2016-06-02 EP EP22188609.6A patent/EP4112618A1/en active Pending
- 2016-06-02 EA EA201792529A patent/EA039006B1/ru unknown
- 2016-06-02 RS RS20211083A patent/RS62290B1/sr unknown
- 2016-06-02 PT PT167285667T patent/PT3303334T/pt unknown
- 2016-06-02 LT LTEPPCT/US2016/035588T patent/LT3303334T/lt unknown
- 2016-06-02 MX MX2021006571A patent/MX2021006571A/es unknown
- 2016-06-02 CN CN201680000891.8A patent/CN106459049B/zh active Active
- 2016-06-02 CR CR20170593A patent/CR20170593A/es unknown
- 2016-06-02 DK DK16728566.7T patent/DK3303334T3/da active
- 2016-06-02 US US15/578,623 patent/US20180162861A1/en not_active Abandoned
- 2016-06-02 HU HUE16728566A patent/HUE055419T2/hu unknown
- 2016-06-02 SG SG10201912443XA patent/SG10201912443XA/en unknown
- 2016-06-02 AU AU2016270973A patent/AU2016270973B2/en active Active
- 2016-06-02 MY MYPI2017704576A patent/MY190548A/en unknown
- 2016-06-02 TW TW110121130A patent/TWI810582B/zh active
- 2016-06-02 JP JP2017562758A patent/JP6646072B2/ja active Active
- 2016-06-02 EP EP21169631.5A patent/EP3912979A1/en active Pending
- 2016-06-02 PE PE2017002512A patent/PE20180521A1/es unknown
- 2016-06-02 CN CN202011284728.3A patent/CN113149983B/zh active Active
- 2016-06-02 CA CA2987335A patent/CA2987335A1/en active Pending
- 2016-06-02 TN TNP/2017/000501A patent/TN2017000501A1/en unknown
-
2017
- 2017-01-19 US US15/410,716 patent/US9688676B2/en active Active
- 2017-11-27 IL IL255946A patent/IL255946A/en active IP Right Grant
- 2017-12-01 PH PH12017502203A patent/PH12017502203A1/en unknown
- 2017-12-01 CL CL2017003073A patent/CL2017003073A1/es unknown
- 2017-12-01 DO DO2017000279A patent/DOP2017000279A/es unknown
- 2017-12-15 CO CONC2017/0012947A patent/CO2017012947A2/es unknown
-
2018
- 2018-09-11 HK HK18111674.0A patent/HK1252378A1/zh unknown
-
2019
- 2019-07-31 CL CL2019002150A patent/CL2019002150A1/es unknown
-
2020
- 2020-01-08 JP JP2020001139A patent/JP6985433B2/ja active Active
- 2020-05-26 AU AU2020203447A patent/AU2020203447B2/en active Active
- 2020-09-23 US US17/029,184 patent/US20210171526A1/en not_active Abandoned
- 2020-12-07 IL IL279258A patent/IL279258B/en unknown
-
2021
- 2021-08-04 HR HRP20211249TT patent/HRP20211249T1/hr unknown
-
2022
- 2022-10-27 US US17/974,613 patent/US20230151012A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017012947A2 (es) | Inhibidores de tirosina-cinasas | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2018006662A2 (es) | Agonistas del receptor de apelina y métodos de uso | |
CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CO2017011851A2 (es) | Compuestos novedosos | |
CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
ECSP18049420A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
CL2017001459A1 (es) | Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
NZ729603A (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
EA032953B1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
UY36419A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
UY37018A (es) | Inhibidores bicíclicos de pad4 | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
CL2019001092A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas. | |
CL2019001091A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas. | |
WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
BR112017006552A2 (pt) | composições e métodos para inibir a atividade biológica de biomoléculas solúveis | |
CO2017000586A2 (es) | Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida |